Examkin

Question

Difficulty: Very hardAnxiety, OCD, and Trauma-Related Disorders

A 32-year-old male is evaluated at the behavioral health center for profound distress. Five months prior, he witnessed a catastrophic scaffolding collapse at his construction site. Since the incident, he suffers from severe hyperarousal, nightly harrowing dreams about the collapse, and active avoidance of any construction zones. He feels emotionally estranged from his spouse. Over the previous six weeks, he has also manifested a severely depressed affect, extreme fatigue, and complete loss of interest in his usual recreational activities.

Review of his psychiatric history reveals an involuntary psychiatric admission at age 23. During that 18-day admission, he exhibited expansive mood, pressured speech, a perceived lack of need for sleep, and auditory hallucinations of a voice declaring him 'the chosen architect.' These hallucinations ceased entirely within days of mood stabilization.

Five days ago, the patient abruptly stopped taking phenelzine—prescribed by a different provider for his low mood—due to his inability to maintain the required dietary restrictions. He is currently taking no medications.

Which of the following represents the most appropriate next step in management?

  1. A
    Delay pharmacotherapy for 9 days, followed by the introduction of paroxetine alone
  2. B
    Notify his construction manager to mandate a transfer to administrative duties
  3. Begin lithium and arrange for trauma-focused psychotherapyAnswer
  4. D
    Classify his previous presentation as schizophreniform disorder and begin risperidone
  5. E
    Prescribe immediate citalopram to address both his trauma-related and depressive symptoms

Answer

The most appropriate next step is to initiate a mood stabilizer that does not interact with MAOIs (like lithium) and refer the patient for trauma-focused psychotherapy.
The correct management strategy safely addresses this complex patient's multiple psychiatric conditions. He is suffering from Post-Traumatic Stress Disorder (PTSD) and a major depressive episode. However, his history of an 18-day hospitalization for expansive mood, decreased need for sleep, and psychotic features indicates an underlying diagnosis of Bipolar I Disorder. Furthermore, he discontinued phenelzine (an MAOI) only 5 days ago. Because MAOIs irreversibly inhibit monoamine oxidase, starting any serotonergic agent (like an SSRI) within 14 days risks life-threatening serotonin syndrome. Lithium is an effective mood stabilizer for bipolar depression that has no serotonergic interaction with MAOIs, making it safe to initiate immediately. Concurrently, trauma-focused psychotherapy is the first-line, evidence-based treatment for PTSD and carries no pharmacological risks.

Step-by-Step Solution

1
Evaluate the current symptom profile against DSM-5 criteria.
The patient meets criteria for Post-Traumatic Stress Disorder (PTSD) and is currently experiencing a major depressive episode.
Establishing the current acute diagnoses identifies the primary targets for immediate treatment.
2
Analyze the past psychiatric history.
The prior 18-day hospitalization for expansive mood, decreased sleep, and hallucinations that resolved with mood stabilization confirms an underlying diagnosis of Bipolar I Disorder with psychotic features.
A history of mania fundamentally alters the pharmacological management of current depressive or anxiety symptoms.
3
Assess the pharmacological constraints imposed by recent medication use.
The patient discontinued phenelzine (an MAOI) 5 days ago. A strict 14-day washout period is required before starting any serotonergic medications.
MAOIs irreversibly inhibit monoamine oxidase; combining them (or starting serotonergic drugs before enzyme regeneration) causes life-threatening serotonin syndrome.
4
Select a safe and effective management plan that addresses all constraints.
Begin lithium and arrange for trauma-focused psychotherapy.
Lithium treats bipolar depression without serotonin syndrome risk, and trauma-focused psychotherapy is the first-line, non-pharmacological treatment for PTSD.

Key Concept

Complex management of PTSD and bipolar depression in the context of recent MAOI discontinuation.

Alternative Method

If lithium is contraindicated (e.g., due to severe renal impairment), valproate or an atypical antipsychotic approved for bipolar depression (such as quetiapine or lurasidone) could be initiated instead, as they also do not carry a risk of serotonin syndrome.
Estimated Time:2m 30s
Rate this question

Topics

Anxiety, OCD, and Trauma-Related Disorders

More questions from this topic